# Xinglian Biotechnology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/xinglian-biotechnology

- Industry: Biotechnology
- Headquarters: Tianjin, China
- Website: www.conjustar.com
- Total disclosed funding: $15M
- Latest round: Angel (Feb 21, 2023)
- Investors on record: 4

## About

Based in Tianjin, China, and founded in 2022, Xinglian Biotechnology operates as a biotechnology developer, specializing in the development of protein-coupled drugs. In February 2023, the company has completed a CNY 55 million angel funding. In 2024, it established the Zhuhai Research Center. In January 2025, it raised CNY 100 million in pre-series A+ funding.

Xinglian Biotechnology focuses on the research and development of protein-coupled drugs and has established pipelines through a combination of external introduction and in-house R&D. The company's product pipeline can be used to treat tumors.

The company generates revenue by developing protein-coupled drugs.

The company will use the funds to develop clinical trials of core products and new products to accelerate the clinical transformation of XDC drugs.

## Funding rounds

- Angel, Feb 21, 2023, $7.9M — Tahoe VC, Wuxi AppTec Group, Fosun Health Capital, Shunrui Enterprise Management
- Seed, Mar 8, 2022, $7.2M — Wuxi AppTec Group, Fosun Health Capital

## Investors

- Wuxi AppTec Group — Seed, Angel
- Fosun Health Capital (https://capitalatlas.ai/funds/fosun-health-capital) — Seed, Angel
- Tahoe VC — Angel
- Shunrui Enterprise Management — Angel